Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
MedPlus's subsidiary Optival Health Solutions received a 25-day suspension order for the Drug License of its Medplus Dattatray Nagar store in Nagpur, Maharashtra, from the Food & Drug Administration authorities. The order, received on June 4, 2025, was issued under Rule 65 of the Drugs and Cosmetics Act, 1940. The company estimates a potential revenue loss of about Rs 7 lakhs due to this suspension. MedPlus has not elaborated on the specific reason for the suspension, and the financial impact is disclosed as quantifiable only to this limited extent.
The impact is minor — a ~Rs 7 lakh potential revenue loss from a single store's 25-day license suspension is negligible for a large pharmacy chain like MedPlus. Shareholders are unlikely to see any meaningful effect on earnings or stock price from this isolated regulatory action.